At a compound annual growth rate of 8.8 %, the size of the worldwide Post-Marketing Pharmacovigilance market is projected to reach US$ 11.5 Bn in 2028.
The global post marketing pharmocovigillence market is segmented into several classifications including phase outlook, service provider outlook, end-use outlook, methods of outlook, end use outlook, and regional outlook. Based on the phase outlook the global marketing pharmocovigillence industry is categorized pre-clinical, phase I, phase II, phase III, and phase IV. Furthermore, on the basis of service provider outlook the global marketing pharmocovigillence market is subjected to in-house, contract outsourcing. On the basis of methods outlook the global marketing pharmocovigillence market is divided into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining. On the basis of end use outlook the global marketing pharmocovigillence industry is classified into hospital, research organizations, and industrial.
In terms of geography, the global post marketing pharmocovigillence market is widely range to North America, U.S., Canada, Europe, UK, Germany, Asia Pacific, Japan, China, India, Latin America, Brazil, Mexico, MEA, and South Africa.
In 2014, North America held the largest revenue share of overall industry. However due to growing demand for new drug development coupled with incidences of adverse drug reporting are one of the prime driver for this regional market. Increasing adoption rate of Electronic Health Records (EHR), healthcare expenditure, and supportive infrastructure are further anticipated to fuel growth of this regional industry. Asia Pacific region is anticipated to show lucrative growth in future due to increasing outsourcing activities, rising demand for pharmacovilligence activities, and improving healthcare infrastructure.
The post marketing pharmocovigillence market is highly competitive in nature and manufacturers are moreover concentrating on strategies such as collaborative agreements, merger & acquisition, new product development for sustaining the competition and gain more industry share. Presence of an environment has efficiently led to the streamlining of R&D, medical writing, pharmacovigillience, clinical data management, and manufacturing operations.
Leading players of the global marketing pharmocovigillence market include Accenture Plc, Clinquest Group, B.V., Cognizant Technology Solutions Corp., Covance Inc., iMEDGlobal Corp., inVentiv Health Clinical, Parexel International Corporation, Pharmaceutical Product Development Inc, PRA Health Sciences, Quintiles Transnational Corporation, F. Hoffmann-La Roche Ltd. Sanofi, Synowledge, Wipro Ltd., ArisGlobal and Ergomed.
Post Marketing Pharmocovigillence Market Scope
Metrics | Details |
Base Year | 2022 |
Historic Data | 2018-2019 |
Forecast Period | 2022-2028 |
Study Period | 2018-2028 |
Forecast Unit | Value (USD) |
Revenue forecast in 2028 | US$ 11.5 Bn |
Growth Rate | CAGR of 8.8% during 2018-2028 |
Segment Covered | By Product, Regions |
Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, South America |
Key Players Profiled | Accenture Plc; Clinquest Group, B.V.; Cognizant Technology Solutions Corp.; Covance Inc.; iMEDGlobal Corp.; inVentiv Health Clinical; Parexel International Corporation; Pharmaceutical Product Development Inc; PRA Health Sciences; Quintiles Transnational Corporation; F. Hoffmann-La Roche Ltd. Sanofi; Synowledge; Wipro Ltd.; ArisGlobal; Ergomed |
Key Segmentation of the Global Post Marketing Pharmocovigillence Market
Pharmacovigilance Clinical Trial Phase Outlook (USD Billion)
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Phase IV
Pharmacovigilance Service Provider Outlook (USD Billion)
- In-house
- Contract Outsourcing
Pharmacovigilance Type of Methods Outlook (USD Billion)
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
Pharmacovigilance End Use Outlook (USD Billion)
- Hospitals
- Research Organizations
- Industrial
Pharmacovigilance Regional Outlook (USD Billion)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa